Crispo, F.; Notarangelo, T.; Pietrafesa, M.; Lettini, G.; Storto, G.; Sgambato, A.; Maddalena, F.; Landriscina, M.
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. Cancers 2019, 11, 1388.
https://doi.org/10.3390/cancers11091388
AMA Style
Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, Maddalena F, Landriscina M.
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. Cancers. 2019; 11(9):1388.
https://doi.org/10.3390/cancers11091388
Chicago/Turabian Style
Crispo, Fabiana, Tiziana Notarangelo, Michele Pietrafesa, Giacomo Lettini, Giovanni Storto, Alessandro Sgambato, Francesca Maddalena, and Matteo Landriscina.
2019. "BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives" Cancers 11, no. 9: 1388.
https://doi.org/10.3390/cancers11091388
APA Style
Crispo, F., Notarangelo, T., Pietrafesa, M., Lettini, G., Storto, G., Sgambato, A., Maddalena, F., & Landriscina, M.
(2019). BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. Cancers, 11(9), 1388.
https://doi.org/10.3390/cancers11091388